T1, T2, PD values, and VMY determined via quantitative synthetic MRI pre- and postadministration of gadolinium-based contrast agenta

VMY (%)T1 (ms)T2 (ms)PD (%)
With metastases pre-GBCA21.14 ± 1.831061.68 ± 59.8099.26 ± 12.3775.90 ± 1.99
With metastases post-GBCA21.92 ± 1.671010.35 ± 54.5795.59 ± 13.7574.85 ± 2.02
Difference0.78 ± 0.85b−51.34 ± 43.44b−2.67 ± 9.35c−1.05 ± 1.26b
Without metastases pre-GBCA20.84 ± 1.081076.41 ± 75.4098.43 ± 13.4275.87 ± 1.79
Without metastases post-GBCA21.59 ± 1.011029.58 ± 70.9793.73 ± 15.3974.59 ± 2.03
Difference0.75 ± 0.53d−46.84 ± 31.23d−4.70 ± 12.21b−1.28 ± 1.35b

  • ↵a Data are mean ± SD.

  • ↵b Wilcoxon signed rank test P < .01.

  • ↵c Wilcoxon signed rank test P < .05.

  • ↵d Wilcoxon signed rank test P < .001.